


# AMENDMENTS TO THE CLAIMS

The following listing of claims will replace all versions, and listings, of claims in the application.

1. (Currently amended) A compound of formula (I):



wherein

R<sub>1</sub> is aryl or heteroaryl;

each of R<sub>2</sub> and R<sub>4</sub>, independently, is H, halogen, CN, alkyl, OR<sup>a</sup>, or NR<sup>a</sup>R<sup>b</sup>;

R<sub>3</sub> is H, halogen, CN, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, OR<sup>a</sup>, OC(O)R<sup>a</sup>, OC(O)NR<sup>a</sup>R<sup>b</sup>, NR<sup>a</sup>R<sup>b</sup>, NR<sup>a</sup>C(O)R<sup>b</sup>, NR<sup>a</sup>S(O)R<sup>b</sup>, NR<sup>a</sup>S(O)<sub>2</sub>R<sup>b</sup>, NR<sup>a</sup>C(O)NR<sup>b</sup>R<sup>c</sup>, NR<sup>a</sup>C(S)NR<sup>b</sup>R<sup>c</sup>, NR<sup>a</sup>C(NR<sup>b</sup>)NR<sup>c</sup>R<sup>d</sup>, NR<sup>a</sup>C(O)OR<sup>b</sup>, S(O)NR<sup>a</sup>R<sup>b</sup>, S(O)<sub>2</sub>NR<sup>a</sup>R<sup>b</sup>, S(O)R<sup>a</sup>, S(O)<sub>2</sub>R<sup>a</sup>, C(O)R<sup>a</sup>, C(O)OR<sup>a</sup>, or C(O)NR<sup>a</sup>R<sup>b</sup>;

R<sub>5</sub> is H or alkyl;

n is 0, 1, 2, 3, 4, 5, or 6;

A is O, S, S(O), S(O)<sub>2</sub>, or NR<sup>e</sup>;

B is N or CR<sup>f</sup>;

X is O, S, S(O), S(O)<sub>2</sub>, NR<sup>e</sup>, or C(O);

Y is a covalent bond, C(O), C=NR<sup>a</sup>, O, S, S(O), S(O)<sub>2</sub>, or NR<sup>e</sup>;

Z is N or CH;

each of U and V, independently, is N or CR;

W is O, S, or NR<sup>e</sup>;

in which each of  $R^a$ ,  $R^b$ ,  $R^c$ , and  $R^d$ , independently, is H, alkyl, aryl, heteroaryl, cyclyl, or heterocyclyl;  $R^e$  is H, alkyl, aryl, acyl, or ~~sulfonyl~~sulfonyl; and  $R^f$  is H, alkyl, aryl, acyl, sulfonyl, alkoxyl, amino, ester, amide, CN, or halogen; and

provided that if each of U and V is N, Y is a covalent bond, n is 0, then  $R_3$  is H, CN, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cyclyl,  $OR^a$ ,  $OC(O)R^a$ ,  $OC(O)NR^aR^b$ ,  $NR^aR^b$ ,  $NR^aC(O)R^b$ ,  $NR^aS(O)R^b$ ,  $NR^aS(O)_2R^b$ ,  $NR^aC(O)NR^bR^c$ ,  $NR^aC(S)NR^bR^c$ ,  $NR^aC(NR^b)NR^cR^d$ ,  $NR^aC(O)OR^b$ ,  $S(O)NR^aR^b$ ,  $S(O)_2NR^aR^b$ ,  $S(O)R^a$ ,  $S(O)_2R^a$ ,  $C(O)R^a$ ,  $C(O)OR^a$ , or  $C(O)NR^aR^b$ .

2. (Cancelled)

3. (Original) The compound of claim 1, wherein Z is N.

4. (Original) The compound of claim 3, wherein W is O.

5. (Original) The compound of claim 1, wherein X is  $NR^e$ .

6. (Cancelled)

7. (Cancelled)

8. (Currently amended) The compound of claim 1 6, wherein Z is N.


9. (Original) The compound of claim 8, wherein W is O.

10. (Currently amended) The compound of claim 8 6, wherein X is  $NR^e$ .

11. (Cancelled)

12. (Cancelled)


13. (Currently amended) The compound of claim ~~12~~10, wherein W is O.
14. (Currently amended) The compound of claim ~~12~~ 10, wherein R<sub>3</sub> is halogen, CN, alkyl, aryl, ~~heteroaryl~~ ~~heteroaryl~~, OR<sup>a</sup>, OC(O)R<sup>a</sup>, NR<sup>a</sup>NR<sup>b</sup>, NR<sup>a</sup>C(O)R<sup>b</sup>, C(O)OR<sup>a</sup>, or C(O)NR<sup>a</sup>R<sup>b</sup>.
15. (Currently amended) The compound of claim 14, wherein R<sub>3</sub> is aryl, heteroaryl, aryloxy, or ~~heteroaryloxy~~ ~~heteroaryloxy~~.
16. (Original) The compound of claim 15, wherein R<sub>3</sub> is heteroaryl.
17. (Original) The compound of claim 15, wherein R<sub>3</sub> is pyridinyl, triazolyl, tetrazolyl, pyrimidinyl, thiazolyl, indolyl, or indolizinyl.
18. (Original) The compound of claim 15, wherein the compound is a *N*-oxide.
19. (Original) The compound of claim 13, wherein R<sub>1</sub> is aryl.
20. (Original) The compound of claim 19, wherein Y is NR<sup>e</sup>.
21. (Original) The compound of claim 19, wherein Y is O.
22. (Currently amended) The compound of claim 19, wherein R<sub>1</sub> is



in which R<sup>g</sup> is H, halogen, CN, alkyl, or alkoxy; R<sup>h</sup> is halogen, CN, hydroxyl, amino, alkyl, aryl, heteroaryl, alkoxy, aryloxy, heteroaryloxy, acyl, alkoxycarbonyl, alkylcarbonoxyl, mono- and


dialkylaminocarbonyl, amidinyl, ureayl, guanadiny, sulfonyl, or sulfonamidyl ~~sulfonamidyl~~; and m is 0, 1, 2, 3, or 4.






23. (Original) The compound of claim 22, wherein  $R_1$  is













24. (Original) The compound of claim 22, wherein  $R^g$  is H, F, Cl, Br, I, CN, Me, Et, Pr, *i*-Pr, OMe, or OEt.

25. (Currently amended) The compound of claim 1, wherein the compound is








, or

26. (Withdrawn – Currently amended) A method for treating an interleukin-12 overproduction-related disorder, comprising administering to a subject in need thereof an effective amount of a the compound of formula (I):



wherein

$R_1$  is aryl or heteroaryl;

each of  $R_2$  and  $R_4$ , independently, is H, halogen, CN, alkyl,  $OR^a$ , or  $NR^aR^b$ ;

$R_3$  is H, halogen, CN, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl,  $OR^a$ ,  $OC(O)R^a$ ,  $OC(O)NR^aR^b$ ,  $NR^aR^b$ ,  $NR^aC(O)R^b$ ,  $NR^aS(O)R^b$ ,  $NR^aS(O)_2R^b$ ,  $NR^aC(O)NR^bR^c$ ,  $NR^aC(S)NR^bR^c$ ,  $NR^aC(NR^b)NR^cR^d$ ,  $NR^aC(O)OR^b$ ,  $S(O)NR^aR^b$ ,  $S(O)_2NR^aR^b$ ,  $S(O)R^a$ ,  $S(O)_2R^a$ ,  $C(O)R^a$ ,  $C(O)OR^a$ , or  $C(O)NR^aR^b$ ;

$R_5$  is H or alkyl;

$n$  is 0, 1, 2, 3, 4, 5, or 6;

A is O, S,  $S(O)$ ,  $S(O)_2$ , or  $NR^e$ ;

B is N or  $CR^f$ ;

X is O, S,  $S(O)$ ,  $S(O)_2$ ,  $NR^e$ , or  $C(O)$ ;

Y is a covalent bond,  $C(O)$ ,  $C=NR^a$ , O, S,  $S(O)$ ,  $S(O)_2$ , or  $NR^e$ ;

Z is N or CH;

each of U and V, independently, is N or  $CR$ ; and

W is O, S, or  $NR^e$ ;

in which each of  $R^a$ ,  $R^b$ ,  $R^c$ , and  $R^d$ , independently, is H, alkyl, aryl, heteroaryl, cyclyl, or heterocyclyl;  $R^e$  is H, alkyl, aryl, acyl, or sulfonyl ~~sulfonyl~~; and  $R^f$  is H, alkyl, aryl, acyl, sulfonyl, alkoxyl, amino, ester, amide, CN, or halogen.

27. (Cancelled)

28. (Withdrawn) The method of claim 26, wherein Z is N.

29. (Withdrawn) The method of claim 28, wherein W is O.

30. (Withdrawn) The method of claim 26, wherein X is NR<sup>e</sup>.

31. (Cancelled)

32. (Withdrawn) The method of claim 26, wherein the disorder is rheumatoid arthritis, sepsis, Crohn's disease, multiple sclerosis, psoriasis, or insulin-dependent diabetes mellitus.

33. (Cancelled)

34. (Withdrawn – Currently amended) The method of claim 26 ~~32~~, wherein Z is N.









35. (Withdrawn) The method of claim 34, wherein W is O.











36. (Withdrawn – Currently amended) The method of claim 26 ~~32~~, wherein X is NR<sup>e</sup>.











37. (Cancelled)











38. (Withdrawn – Currently amended) The method of claim 26, wherein the compound is
































, or